Grepafloxacin
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Structural formula without stereochemistry | ||||||||||||||||||||||
General | ||||||||||||||||||||||
Non-proprietary name | Grepafloxacin | |||||||||||||||||||||
other names |
|
|||||||||||||||||||||
Molecular formula | C 19 H 22 FN 3 O 3 | |||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class | ||||||||||||||||||||||
Mechanism of action | ||||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 359.39 g · mol -1 | |||||||||||||||||||||
Physical state |
firmly |
|||||||||||||||||||||
Melting point |
206-208 ° C |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Grepafloxacin is a broad spectrum antibiotic belonging to the group of fluoroquinolones . Antibiotics from the group of fluoroquinolones are a subgroup of the quinolones , they act as gyrase inhibitors against gram-positive bacteria ( hemophilus , legionella , mycoplasma , chlamydia, etc.), especially in respiratory infections.
Grepafloxacin was patented in 1989 by the pharmaceutical company Warner-Lambert (now Pfizer ). After some patients as a side effect of the long QT syndrome , an arrhythmia occurred with seven deaths associated with taking the drug, it was taken by the manufacturer end of October 1999 worldwide from the market.
Stereochemistry
Grepafloxacin contains a stereocenter and consists of two enantiomers. This is a racemate , i.e. a 1: 1 mixture of ( R ) - and ( S ) -form:
Grepafloxacin enantiomers | |
---|---|
CAS number: 146761-68-4 |
CAS number: 146761-69-5 |
literature
- W. Forth, D. Henschler, W. Rummel: General and special pharmacology and toxicology . 9th edition. URBAN & FISCHER, Munich 2005, ISBN 3-437-42521-8 .
Individual evidence
- ↑ a b Entry on grepafloxacin. In: Römpp Online . Georg Thieme Verlag, accessed on May 30, 2014.
- ↑ harmonized classification for this substance . A labeling of grepafloxacin in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on May 26, 2020, is reproduced from a self-classification by the distributor . There is not yet a
- ↑ FURTHER CRASH CANDIDATES? CARDIOTOXICITY OF GYRASIS inhibitors . Remedy telegram . S. 120 November 1999. Retrieved June 4, 2009.